NFKB1 and ulcerative colitis: This FMT, as well as phloretin treatment, ameliorated ulcerative colitis by improving pathological markers (e.g., reversing the shortening of colon length and increased Muc2 mRNA and Claudin-1, zonula occludens-1 (ZO-1) protein expressions) and colon inflammation (suppression of cytokines including TNF-α, IL-6 and IL-1β, NF-κB and NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation) and oxidative stress (increase the levels of SOD and GSH and decreasing MDA) markers in colonic tissues.